Lung & Colon Cancer (30 genes) Solution is a targeted sequencing assay for biomarker analysis of over 30 genes known to be relevant to lung cancer and colorectal cancer. It covers gene testing targets approved by the FDA and NMPA and recommended in NCCN and CSCO guidelines. This hybrid capture-based test detects single nucleotide variants (SNVs), insertions/deletions (InDels), amplifications, and fusions. Test results can provide references for individualized therapy, such as targeted medication, immunotherapy, genetic risk assessment, and prognostic indication.
It is capable of detecting low-frequency variants as low as 0.2% in ctDNA, and supports both tissue and liquid biopsy samples
It is capable of detecting multiple types of variants including SNVs, InDels and Amplifications, and also adds the detection of the regions of ROS1 fusion partners CD74, SDC4, SLC34A2 and EZR
BAT-25, BAT-26, NR-21, NR-22, NR-24, NR-27, MONO-27, D2S123, D5S346, and D17S250
100+ unlinked SNP loci. Capable of detecting cross - individual human contamination at a minimum level of 1%
|
Product |
Lung & Colon Cancer 30 Panel |
||||
|
Methods |
Hybrid capture |
||||
|
Gene number |
30+ |
||||
|
Panel size |
340 kb |
||||
|
Variants type |
SNVs, InDels, CNVs, SVs |
||||
|
Input quantity |
20 ng ~ 500 ng DNA |
||||
|
Sample types |
FFPE, fresh tissue, plasma, white blood cells, pleural fluid and ascitic fluid |
||||
|
Mapping rate |
98.99% |
||||
|
On-target rate |
>70% |
||||
|
Coverage uniformity |
97% |
||||
|
Sequencing platform（PE150） |
FASTASeq 300 |
GenoLab M |
SURFSeq 5000 |
FASTASeq S |
|
|
No.of sample/FC |
Tissue/White blood cell (≥1 Gb) |
1 FCM: 20 1 FCH: 48 1 FCP：96 |
1 FCM: 48 1 FCH: 96 |
1 FCM: 96 1 FCH: 400 1 FCP：720 |
1 FCL: 4 1 FCM: 8 |
|
Plasma (≥7 Gb) |
1 FCM: 4 1 FCH: 8 1 FCP：16 |
1 FCM: 8 1 FCH: 16 |
1 FCM: 16 1 FCH: 72 1 FCP：144 |
1 FCM: 1 |
|
|
Turn-around-time |
3-5 days |
||||
|
Report generation |
Local analysis and report system |
||||
